Most of the weight-loss medications right nowWegovy, Zepbound, and otherswork by targeting the GLP-1 pathway
In fact, around 85% of patients encounter this phase, which stems from a mix of factors like metabolic shifts, dosage challenges, muscle loss, hidden calories, reduced activity, hormonal changes, and natural body weight set points
Monitoring confirms these beneficial effects occur as expected
If these treatments help address root causes such as metabolic dysfunction and inflammation, they could potentially have a positive impact on bipolar symptoms as well
The bodys ability to heal itself is just shy of miraculous
These effects are primarily mediated by the inhibition of NF-B and mitogen-activated protein kinase (MAPK) pathways, both of which are associated with stress, inflammation, and apoptosis responses (10, 42)